Keep up to date on AgNovos events and related news
AgNovos Healthcare is pleased to announce the publication of a manuscript titled “AGN1 implant material to treat bone loss: Resorbable implant forms normal bone with and without alendronate in a canine critical size humeral defect model” in the peer-reviewed journal Bone.
AgNovos Healthcare is pleased to announce an exclusive option agreement with Asahi Kasei Pharma Corporation.
AgNovos Healthcare, a developer of medical technology products leveraging regenerative medicine to treat the local effects of bone disease, announced today that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) kit has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration.
The recently issued press release on the FDA's "Breakthrough Designation" for AgNovos' newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has generated a strong of interest in the industry and has been posted on several reputable press portals.
AgNovos Healthcare is pleased to announce that its newest investigational product, AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
The study titled Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures (RESTORE) is a randomized, controlled, prospective, single blinded, multi-national study.